CapForce Inc. · OTC:CFOR
CapForce — Opgen — Investor Presentation (January 2018)
27 slides from CapForce's investor presentation, Jan 9, 2018
Slide 1: Corporate Presentation January 2018
fq@OpGen’ CORPORATE PRESENTATION January 2018 f@OpGen
Slide 2: Forward-looking statements
This presentation includes statements relating to the company's Acuitas® MDRO and Acuitas Lighthouse® clinical laboratory services, FDA cleared QuickFISH® products, and commercialization plans for these products and services. These statements and other statements regarding our future plans and goals
Slide 3: OpGen company and investment highlights
•OpGen is a precision medicine informatics company focused on the rapidly growing Multi-Drug Resistant Organism (MDRO) market -Collaboration and investment from Merck provides differentiated competitive advantage •Addressing a significant global challenge and market opportunity ->$2 billion market i
Slide 4: Recent accomplishments
•AMR Gene Panel u5.47 for Complicated Urinary Tract Infection (cUTI) Produced first RUO test kits üCompleted Analytical Verification studies for RUO product üInitiated Clinical Verification studies with flagship IDN hospitals for RUO product üImplemented Thermo Fisher QuantStudio™ 5 (QS5) Global Sup
Slide 5: 2018 objectives
•Q1 RUO release for AMR Gene Panel u5.47 for clinical isolate testing and cUTI research studies •Completing 3rd party RUO Clinical Verification studies and FDA clinical trials for IVD u5.47 •Making FDA 510(k) submission of u5.47 Gene Panel to support full commercial launch •Adding QS5 and Qiagen EZ1
Slide 6: Revolutionary Approach to Antibiotic Decision Making
Revolutionary Approach to Antibiotic Decision Making OpGen Solution in Hours‘ F@OPGEN’ «inseciomer Ww Current: 2-6 days Empiric Pathogen antibiotic identification pikes x ———— . Pathogen A A DNA Test Lighthouse Right | Knowledgebase Antibiotic Acuitas® Rapid Test: 3 hours First AMR Gene Panel RUO Re
Slide 7: Acuitas Lighthouse: A Proprietary, Curated MDRO Genomic Knowledgebase
Acuitas Lighthouse: A Proprietary, Curated MDRO Genomic Knowledgebase Data Sources feed the OpGen Analytics Models which power the Commercial Applications Insights to power Drug rapid diagnostics susceptibility and optimized testing patient-specific Merck SMART interventions Pathogen Archive Lightho
Slide 8: Acuitas AMR Gene Panel u5.47 & Acuitas Lighthouse Knowledgebase
Acuitas AMR Gene Panel u5.47 & Acuitas Lighthouse Knowledgebase’ © DETECTS: 5 pathogens 47 resistance genes and mutations PREDICTS RESISTANCE FOR: 12 antibiotics SPECIMEN TYPES: Urine Isolates Fa OPGEN’ “ircevecrer ortcerentzeony ff (©2018 OpGer, In. CUITAS LIGHTHOUSE” = AISnOR. la & a ee =< Sas so
Slide 9: Acuitas AMR Gene Panel u5.47 Workflow
Acuitas AMR Gene Panel u5.47 Workflow’ a Tal @ACUTTAS la é, é =a 4 urine specimens or culture isolates / plate Sample Processing i a Vv Extract DNA on Qiagen EZ1 Advance XL 2.5 Hours F@OPGEN” “rserccrmee rresxen con (©2018 OpGer, In.
Slide 10: Acuitas AMR Gene Panel u5.47 Pathogen Targets
Acuitas AMR Gene Panel u5.47 Pathogen Targets’ Species Identification E. coli ID Assay Isolates Correctly Identified Expected Cross-Activity Ft E.coli 88 of 88 (100%) some Shigella spp. E. faecalis © Joecas 65.06 (100%) . K. pneumoniae/variicola 87 of 88 (99%) K. pneumoniae P. aeruginosa 91 of 91 (1
Slide 11: Acuitas Lighthouse Antibiotic Resistance Prediction
Acuitas Lighthouse Antibiotic Resistance Prediction Final training set data and program update * 2million Lighthouse data points evaluated from Merck SMART surveillance network * 41 unique prediction algorithms coded into Lighthouse reporting engine ° Final training set data supporting prediction al
Slide 12: Rapid Complicated Urinary Tract Infection Management
Rapid Complicated Urinary Tract Infection Management * OpGen — <3 Hours* Current — 2+ Days Culture + MALDI + AST 1.5 million U.S. patients at risk 300 thousand cUTI cases annually “In development f@OpGen’ (©2018 OpGer, In. 2
Slide 13: Acuitas Gene Panel / Lighthouse Regulatory and Commercialization Milestones
Acuitas Gene Panel / Lighthouse Regulatory and Commercialization Milestones Q4 * RUOUS.47 Gene Panel Analytical Verification complete 2017 * Lighthouse prediction algorithms finalized * RUO Clinical Verification studies initiated Qi * Finalize regulatory strategy with FDA 2018 * RUO release Clinical
Slide 14: Acuitas Rapid Test Commercial Strategy
Acuitas Rapid Test Commercial Strategy Fj OPGEN *ssunemnsomsvinsee Economics: Key Commercialization >500 Bed Hospital Milestones 5-10 tests per day 2018 + RUO initial revenue ~3,000 tests per year FDA, CE mark filings ol IVD development/licensing agreements $150-$200 ASP ¥ Estimated $500 million ann
Slide 15: Strategic Partners and OpGen Brand
OpGen Brand: •Global supply agreement with Thermo Fisher Scientific for QuantStudio™ 5 Rapid PCR Technology •Additional tests & new drug indications •Health system development collaborations •Geographic expansion Strategic Partners: •Expanded channel access on established Rapid IVD platforms •Access
Slide 16: Large Market for Precision Medicine MDRO Solutions
Large Market for Precision Medicine MDRO Solutions Lead Product: cUTI, Clinical Isolates. Second Product Target: Lower Respiratory Infection * $2B Global Market * 19% CAGR: One of the fastest growing U.S. molecular diagnostic segments * Multiple high-acuity patient types \d Forecast, 2013-2019 f@OpG
Slide 17: Leveraging Acuitas Lighthouse into New Markets and Channels
Leveraging Acuitas Lighthouse into New Markets and Channels 3" Party IVD Development + Lighthouse Informatics 3" Party IVD Development + Lighthouse Informatics Acuitas Rapid DNA Tests + Lighthouse Informatics Bishan MO gaLe Be Acuitas Rapid DNA Tests + Acuitas Rapid DNA Tests + Lighthouse Informatic
Slide 18: Acuitas Lighthouse Information Services - Commercial Opportunities
Acuitas Lighthouse Information Services —- Commercial Opportunities Patient safety & patient registries New antibiotic clinical trials, launches & diagnostics Health Systems Lighthouse ». Knowledgebase 4 Government Proprietary content & informatics f@OpGen’ Or Antimicrobial resistance e (AMR) fundin
Slide 19: CDC Smartphone Clinical Decision Support Award
CDC Smartphone Clinical Decision Support Award Develop clinical decision support solutions for antimicrobial stewardship (AMS) and infection control in low- and middle-income countries. * $860,000 one year award * Teaming Partners: IlUm (Merck HSS); Universidad El Bosque, Colombia e Plan to connect
Slide 20: Merck collaboration and investment
•Merck Global Health Investment Fund invests where Merck’s expertise can help accelerate revenue growth and enhance value creation -$10.5 million investment (May 2016, July 2015) •November 2016: Research collaboration with Merck to develop novel rapid diagnostics and informatics tools to combat anti
Slide 21: Acuitas Lighthouse Revenue Streams
Acuitas Lighthouse Revenue Streams Analytics and Data/Revenue Streams interfaces providing vast amounts of data Acuitas Rapid Test” Urine Respiratory Blood Lighthouse Knowledgebase Hospitals Antibiotic stewardship Patient safety Pharma Surveillan al trials New drug launches Every data stream adds to
Slide 22: OpGen - Developing Breakthrough Microbiology Capabilities
OpGen — Developing Breakthrough Microbiology Capabilities F@OpGen’ a Oo CD oananen Ss @acceLennre a ©@BD bd hese Se one crn “curetis E A GenMarkox g Molecular 2enMarko = iia PEG NT d KJ ca T28losystems: La Slow a Fast Time to Result f@OpGen’ (©2018 OpGer, In. 22
Slide 23: Experienced Leadership Team
Experienced Leadership Team Evan Jones FOUNDATION Chairman & Chief Executive Officer EXDIGENE ia Y veracyre Timothy Dec ~~ ThermoFisher Chief Financial Officer corvis SCIENTIFIC Vadim Sapiro Chief Information Officer JITIGR J. Craig Venter” A nenstmteronccoucreserce resTirugre Terry Walker, Ph.D. SV
Slide 24: Revenue and Balance Sheet
Revenue •$2.2 million total revenue through September 30, 2017 •$4.0 million total revenue in 2016 ̶$3.1 million from ongoing FISH business ̶$0.9 million from legacy and other Balance Sheet •Raised $8.8 million in net proceeds in July 2017 •Cash balance $4.9 million •$11.5 million ATM program (raise
Slide 25: Near-Term Milestones
Near-Term Milestones f@OpGen’ Initial Acuitas Gene Panel RUO commercialization Acuitas RUO Clinical Verification, IVD FDA clinical trial CDC Smartphone Pilot evaluation Acuitas Gene Panel IVD FDA submission Rapid IVD commercialization partnerships Third-party development funding Acuitas AMR Gene Pan
Slide 26: OpGen company and investment highlights
•OpGen is a precision medicine informatics company focused on the rapidly growing Multi-Drug Resistant Organism (MDRO) market -Collaboration and investment from Merck provides differentiated competitive advantage •Addressing a significant global challenge and market opportunity ->$2 billion market i
Slide 27: Thank You
fq@OpGen’ CORPORATE PRESENTATION Thank You f@OpGen